Clinical Trial: A multicenter, prospective, single-arm clinical study of Iparomlimab and Tuvonralimab (QL1706) plus local chemotherapy combined with drug-eluting bead bronchial artery chemoembolization as first-line treatment for unresectable locally advanced non-small cell lung cancer (China)

China, Oct. 27 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A multicenter, prospective, single-arm clinical study of Iparomlimab and Tuvonralimab (QL1706) plus local chemotherapy combined with drug-eluting bead bronchial artery chemoembolization as first-line treatment for unresectable locally advanced non-small cell lung cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135133

Registration Time: 2026/10/26

Type: Interventional study

Primary Sponsor: Hunan Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349139

Published by HT Digital Content Services with permission from Health Daily Diges...